China says Nvidia violated anti-monopoly law-March 2024-www.financetom.com

China says Nvidia violated anti-monopoly law

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

China says Nvidia violated anti-monopoly law

Sep 15, 2025 1:29 AM

BEIJING, Sept 15 (Reuters) - China will continue an

investigation into Nvidia ( NVDA ) after preliminary findings showed that

the company had violated the country's anti-monopoly law,

China's market regulator said on Monday in a statement.

Previous page： DallasNews Files Proxy Statement for Proposed Buyout by Hearst Next page： Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

DallasNews Files Proxy Statement for Proposed Buyout by Hearst

Aug 18, 2025

08:03 AM EDT, 08/18/2025 (MT Newswires) -- DallasNews ( DALN ) said Monday it has filed a definitive proxy statement for its proposed acquisition by Hearst. Under Hearst's proposal, DallasNews ( DALN ) shareholders will receive $15 per share in cash, implying a premium of 242% over the company's last class A share price close of $4.39 before the proposal...

Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says

Aug 18, 2025

08:01 AM EDT, 08/18/2025 (MT Newswires) -- Sunrun ( RUN ) is likely to offer longer-term demand visibility due to the US Treasury outlook, which will also help the company largely eliminate the uncertainty under President Trump's executive order for stringent Treasury guidance on enforcement of commerce construction rules, RBC said in a Monday note. The company's value proposition lies...

Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients

Aug 18, 2025

08:01 AM EDT, 08/18/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Monday said the latest data update from the Phase 1/2 Tuscany trial in newly diagnosed acute myeloid leukemia (AML) patients show no significant safety concerns with different dose levels of the company's lead candidate, tuspetinib. The trial was initiated last December. Data from 10 patients across all...

Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease

Aug 18, 2025

08:04 AM EDT, 08/18/2025 (MT Newswires) -- Soligenix ( SNGX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels. The decision was made after a review of the recent phase 2a clinical results showing biological efficacy and safety in...